Safety Assessment Strategies and Predictive Safety of Biopharmaceuticals and Antibody Drug Conjugates

Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers

Volumn , Issue , 2016, Pages 27-38

  Horner, Michelle J ^a   Hinrichs, Mary Jane ^b   Buss, Nicholas ^b  

^a AMGEN INC   (United States)

^b NONE   (United States)

Author keywords

Antibody drug conjugates; Large molecules; Safety assessment; Small molecule; Species selection; Target biology; Target safety assessment

Indexed keywords

EID: 84994002972     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119053248.ch3     Document Type: Chapter

References (60)

1. Alley SC, Zhang X, Okeley NM, Anderson M, Law C-L, Senter PD, et al. The pharmacologic basis for antibody-auristatin conjugate activity. Journal of Pharmacology and Experimental Therapeutics. 2009; 330(3): 932-8.
2. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Current Opinion in Chemical Biology. 2010; 14(4): 529-37.
3. Aster RH. Drug induced thrombocytopenia. In Platelets (A.D. Michelson, ed.), 2nd ed., pp. 887-902. Burlington, MA:Elsevier; 2007.
4. Attarwala H. TGN1412: from discovery to disaster. Journal of Young Pharmacists. 2010; 2(3): 332-6.
5. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Current Opinion in Molecular Therapeutics. 2009; 11(1): 22-30.
6. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/Nonself-Immune Recognition and Signaling. 2010; 1(4): 314-22.
7. Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Current Opinion in Neurology. 2006; 19(4): 341-9.
8. Beck A, Wurch T, Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology. 2010; 10(5): 345-52.
9. Bracher M, Gould HJ, Sutton BJ, Dombrowicz D, Karagiannis SN. Three-colour flow cytometric method to measure antibodydependent tumor cell killing by cytotoxicity and phagocytosis. Journal of Immunological Methods. 2007; 323(2): 160-71.
10. Brien JD, Sukupolvi-Petty S, Williams KL, Lam CY, Schmid MA, Johnson S, et al. Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. Journal of Virology. 2013; 87(13): 7747-53.
11. Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, et al. Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharmaceutical Research. 2013; 30(7): 1719-28.
12. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Current Opinion in Pharmacology. 2012; 12(5): 615-22.
13. Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, Beyer J, Horvath C. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. International Journal of Toxicology. 2009; 28(3): 230-53.
14. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer Journal (Sudbury, Massachusetts). 2008; 14(3): 154-69.
15. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies:successes, limitations and hopes for the future. British Journal of Pharmacology. 2009; 157(2): 220-33.
16. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology. 2010; 10(5): 301-16.
17. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Accounts of Chemical Research. 2008; 41(1): 98-107.
18. De Groot AS, McMurry J, Moise L. Prediction of immunogenicity:in silico paradigms, ex vivo and in vivo correlates. Current Opinion in Pharmacology. 2008; 8(5): 620-6.
19. De Haan L, Henderson S, McFarlane M, Scott A, Shenton J. Species selection. European Biopharmaceutical Review. 2011; 12(155).
20. Doria-Rose NA, Joyce MG. Strategies to guide the antibody affinity maturation process. Current Opinion in Virology. 2015;11:137-47.
21. EMEA CPMP, Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367), 2007.
22. Expert Scientific Group on Phase 1 Clinical Trials. Final Report, 30 November 2006.
23. Farzaneh L, Kasahara N, Farzaneh F. The strange case of TGN1412. Cancer Immunology, Immunotherapy. 2007; 56(2): 129-34.
24. Finco D, Grimaldi C, Fort M, Walker M, Kiessling A, Wolf B, et al. Cytokine release assays: current practices and future directions. Cytokine. 2014; 66(2): 143-55.
25. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends in Immunology. 2004; 25(3): 158-64.
26. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibodydrug conjugate in development for the treatment of HER2- positive cancer. Cancer Chemotherapy and Pharmacology. 2012; 69(5): 1229-40.
27. Gomez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. Journal of Immunology. 2005; 74(4): 2185-9.
28. Guideline for Requirements for First in Man Clinical Trials for Potential High Risk Medicinal Products. Committee for Medicinal Products for Human Use (CHMP). EMEA/CHMP/SWP/28367/2007. Corr.23 Regulatory Focus 41. May 2007.
29. Green J, Black L. Status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Human & Experimental Toxicology. 2000; 19(4): 208-12.
30. Han TH, Zhao B. ADME considerations for the development of antibody-drug conjugates. Drug Metabolism and Disposition:The Biological Fate of Chemicals. 2014;42:1914-20.
31. Hinrichs MJ, Dixit R. Antibody drug conjugates: nonclinical safety considerations. The AAPS Journal. 2015;17:1055-64.
32. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature Biotechnology. 2005; 23(9): 1126-36.
33. ICH Harmonized Tripartite Guideline M3(R2). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, 2009.
34. ICH Harmonized Tripartite Guideline S6(R1). Note for guidance on preclinical safety evaluation of biotechnology-derived pharmaceuticals, 2011 (CPMP/ICH/302/95).
35. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nature Biotechnology. 2008; 26(8): 925-32.
36. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical Pharmacokinetics. 2010; 49(8): 493-507.
37. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrology, Dialysis, Transplantation. 2006;21 Suppl 5:v9-v12.
38. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008; 7(1): 21-39.
39. Lebrec H, Molinier B, Boverhof D, Collinge M, Freebern W, Henson K, et al. The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: study design, data analysis, interpretation. Regulatory Toxicology and Pharmacology. 2014; 69(1): 7-21.
40. Li N, Ludmann S, He C, Anest L, Narayanan P. Generation of macrophages from cynomolgus bone marrow as a model to estimate effects of drugs on innate immunity. Society for Leukocyte Biology Annual Meeting. 2012;161:S64.
41. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Microtubule Dynamics and Associated Proteins. Molecular Cell Biology. 4th ed. New York: W.H. Freeman; 2000.
42. Mackay C, Terpe H, Stauder R, Marston W, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. The Journal of Cell Biology. 1994; 124(1): 71-82.
43. Meng L, Romano A, Smith E, Macik G, Grosh WW. Disseminated intravascular coagulation and immune hemolytic anemia, possibly evans syndrome, after oxaliplatin and bevacizumab infusion for metastatic colon adenocarcinoma: a case report and literature review. Clinical Colorectal Cancer. 2015;14(1):e1-e3.
44. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Research. 1987; 47(11): 2883-91.
45. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs. 2010; 2(2): 181-9.
46. Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Current Opinion in Biotechnology. 2009; 20(6): 722-9.
47. Persson A, Hober S, Uhlen M. A human protein atlas based on antibody proteomics. Current Opinion in Molecular Therapeutics. 2006; 8(3): 185-90.
48. Pfuhler S, Kirkland D, Kasper P, Hayashi M, Vanparys P, Carmichael P, et al. Reduction of use of animals in regulatory genotoxicity testing:Identification and implementation opportunities-Report from an ECVAM workshop. Mutation Research. 2009;680 (1-2):31-42.
49. Riva MA, Manzoni M, Isimbaldi G, Cesana G, Pagni F. Histochemistry: historical development and current use in pathology. Biotechnic & Histochemistry. 2014; 89(2): 81-90.
50. Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, et al. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. Regulatory Toxicology and Pharmacology. 2013; 67(3): 382-91.
51. Rojko JL, Evans MG, Price SA, Han B, Waine G, DeWitte M, et al. Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes:review and case studies. Toxicologic Pathology. 2014; 42(4): 725-64.
52. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. Journal of Pharmacokinetics and Pharmacodynamics. 2012; 39(1): 67-86.
53. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature Biotechnology. 2012; 30(2): 184-9.
54. Solaro R, Chiellini F, Battisti A. Targeted delivery of protein drugs by nanocarriers. Materials. 2010;3:1929-80.
55. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chemistry & Biology. 2013; 20(2): 161-7.
56. Swanson SJ, Bussiere JL. Immunogenicity assessment in nonclinical studies. Current Opinion in Microbiology 2012;15:1-11.
57. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, et al. Anti-prostate-Specific membrane antigenbased radioimmunotherapy for prostate cancer. Cancer. 2010; 116(S4):1075-83.
58. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clinical Cancer Research. 2006;12(20 Pt 1):6064-72.
59. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies. 2013; 2(1): 113-29.
60. Troyer JK, Beckett ML, Wright GL, Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. International Journal of Cancer Journal International du Cancer. 1995; 62(5): 552-8.